Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

NCT05201859 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Sintilimab
DRUG: Capecitabine

Sponsor

Sun Yat-sen University